SR9009 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
=== Pharmacokinetics === Opipramol is rapidly and completely absorbed by the gastrointestinal tract. The bioavailability of opipramol amounts to 94%. After single oral administration of 50 mg, the peak plasma concentration of the drug is reached after 3.3 hours and amounts to 15.6 ng/mL. After single oral administration of 100 mg the maximum plasma concentration is reached after 3 hours and amounts to 33.2 ng/mL. Therapeutic concentrations of opipramol range from 140 to 550 nmol/L. The plasma protein binding amounts to approximately 91% and the volume of distribution is approximately 10 L/kg. Opipramol is partially metabolized in the liver to deshydroxyethylopipramol. Metabolism occurs through the CYP2D6 isoenzyme. Its terminal half-life in plasma is 6–11 hours. About 70% is eliminated in urine with 10% unaltered. The remaining portion is eliminated through feces.
The UK government rejects a call from Plaid Cymru to devolve responsibility for the Crown Estate in Wales to the Welsh Government, saying it would make no sense to do so. Northern Ireland's Deputy First Minister, Emma Little-Pengelly confirms she will travel to Washington for St Patrick's Day celebrations at the White House. 25 February Keir Starmer announces cuts to international aid to fund an increase of defence spending to 2.5% of GDP by 2027. In her first major speech on foreign policy, Kemi Badenoch said the UK should leave the European Convention on Human Rights (ECHR). Reform UK gains its first representative on Cornwall Council following the defection of Conservative councillor Kevin Towill. Business Secretary Jonathan Reynolds apologises for saying he worked as a solicitor before he became an MP. The first round of cross-party talks on social care reform in England is postponed. 27 February – Starmer meets with US President Donald Trump at the White House for talks on Ukraine and defence. King Charles III invites Trump to the UK for a second state visit. Labour MP Mike Amesbury's prison sentence is suspended following an appeal. 28 February – International Development Minister Anneliese Dodds resigns over the prime minister's cuts to the foreign aid budget, saying the UK's reputation will be deeply harmed. Former Conservative Attorney General Dominic Grieve is appointed by the UK government to lead a review into creating a new definition of Islamophobia.
This myth originated from a misinterpreted joke in a 2013 report of a pacu being found in Øresund, the strait between Sweden and Denmark, which claimed that the fish ate "nuts". Piranhas do not eat only meat but are omnivorous, and they swim in schools only to defend themselves from predators and not to attack. They very rarely attack humans, only when under stress and feeling threatened, and even then, bites typically only occur on hands and feet. Sharks can get cancer. The misconception that sharks do not get cancer was spread by the 1992 book Sharks Don't Get Cancer, which was used to sell extracts of shark cartilage as cancer prevention treatments. Reports of carcinomas in sharks exist, and current data does not support any conclusions about the incidence of tumors in sharks. Great white sharks do not mistake human divers for seals or other pinnipeds. When attacking pinnipeds, the shark surfaces quickly and attacks violently. In contrast, attacks on humans are slower and less violent: the shark charges at a normal pace, bites, and swims off. Great white sharks have efficient eyesight and color vision; the bite is not predatory, but rather for identification of an unfamiliar object. Snake jaws cannot unhinge. The posterior end of the lower jaw bones contains a quadrate bone, allowing jaw extension. The anterior tips of the lower jaw bones are joined by a flexible ligament allowing them to bow outwards, increasing the mouth gape. Snakes are not deaf or only able to sense ground vibrations.
==== Non-deterministic wallet ==== In a non-deterministic wallet, each key is randomly generated independently and is not derived from a common seed. Therefore, any backups of the wallet must store each and every private key used as an address, as well as a buffer of future keys that may have already been issued as addresses but have not yet received payments.
Sources: en.wikipedia.org
Valve, the developers of Source and Half-Life 2, contacted Newman to suggest a commercial, standalone release of the mod through their digital distribution service Steam, which Newman initially rejected. Valve and Facepunch later struck a publishing agreement wherein Valve would release Garry's Mod onto Steam at a price of US$10, while the two companies would equally split profits. The last free version of Garry's Mod remained available for download, rechristened as the demo to the retail game. The standalone game was released on 29 November 2006. Despite the game no longer being a mod, Valve and Facepunch stuck with the "Garry's Mod" name, which Newman later cited as a mistake, stating that he should have called it "Sandbox" instead. Because Garry's Mod still required a separate Source-based game to function properly, a bundle including Garry's Mod and Valve's Counter-Strike: Source was released alongside. A port of the Windows version for Mac OS X was released on 23 September 2010. Support for Kinect, a full-body motion tracking peripheral, was added to the Windows version in December 2012. When Garry's Mod was moved over to Valve's SteamPipe content delivery system, completed on 5 June 2013, an experimental Linux client was also introduced. In 2025, an update to the game added popularly-used assets from Counter-Strike: Source and episodic content from Half-Life 2, addressing a majority of missing content issues found in community maps and caused by not having the aforementioned games installed.
Ag+O2− + H2C=CH2 → (CH2CH2)O + AgO The resulting silver oxide then oxidizes ethylene or ethylene oxide to CO2 and water. This reaction replenishes the silver catalyst. Thus the overall reaction is expressed as
In bioinformatics, the BLOSUM (BLOcks SUbstitution Matrix) matrix is a substitution matrix used for sequence alignment of proteins. BLOSUM matrices are used to score alignments between evolutionarily divergent protein sequences. They are based on local alignments. BLOSUM matrices were first introduced in a paper by Steven Henikoff and Jorja Henikoff. They scanned the BLOCKS database for very conserved regions of protein families (that do not have gaps in the sequence alignment) and then counted the relative frequencies of amino acids and their substitution probabilities. Then, they calculated a log-odds score for each of the 210 possible substitution pairs of the 20 standard amino acids. All BLOSUM matrices are based on observed alignments; they are not extrapolated from comparisons of closely related proteins like the PAM Matrices.
=== Capillary rise of liquid between two glass plates === The product of layer thickness (d) and elevation height (h) is constant (d·h = constant), the two quantities are inversely proportional. The surface of the liquid between the planes is hyperbola.
=== X-Ray Scattering === In 1953, Kaesberg and a few colleagues used x-ray scattering to determine the size and hydration of three different viruses: the southern bean mosaic virus, the tomato bushy stunt virus, and the tobacco necrosis virus. All three of the viruses had a sphere-like shape and internal hydration. They differed, however, in their diameters, with the tobacco necrosis virus having a diameter of 280 angstroms, the southern bean virus having a diameter of 286 angstroms, and the tomato bushy stunt virus having the largest diameter of them all: 309 angstroms. In 1954, Kaesberg and Paul Schmidt utilized small-angle X-ray scattering to measure the size of the yellow turnip mosaic virus and its associated protein. They found that both particles were almost spherical and the same size. They found that while the virus had a relatively constant electron density, the protein was a water-filled shell. In 1963, Margaret Wright and Paul Kaesberg used x-ray scattering to learn more about the inside of the bromegrass mosaic virus. They discovered that the virus had a 260 angstroms diameter and an inner region with an 80-angstrom diameter. Negatively stained bromegrass viruses had a slightly larger internal diameter, about 90 angstroms. They saw that the internal region was almost wholly empty and that the RNA and protein within the virus had almost equal electron densities. However, they noticed something different in the positively stained viruses. These viruses have nucleic acids compacted into a shell formation enveloped by proteins.
Sources: en.wikipedia.org
The set of data generated by the subset of subjects who complied with the protocol sufficiently to ensure that these data would be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of major protocol violations. (ICH E9) Pharmacokinetics
At a meeting of the Pheu Thai Party on 20 March 2022, Paetongtarn was elected as "Head of the Pheu Thai Family". When speaking at the Pheu Thai Party's annual general meeting in April 2022, she said that she wanted to see regime change in Thailand and wanted to gain more experience before standing for the post of the country's prime minister. Paetongtarn became the leading prime minister-candidate in the opinion polls. In April 2023, she was officially nominated as one of the three prime minister-candidates of Pheu Thai Party for the general election, along with Srettha Thavisin and Chaikasem Nitisiri. After the general election in May 2023, the Pheu Thai Party secured the second-highest number of seats in the House of Representatives, following the Move Forward Party. She expressed disappointment that the party did not achieve first place as planned but stated that she was ready to work with the Move Forward Party and other parties willing to form a coalition with both parties. However, after Pheu Thai Party withdrew from the memorandum of understanding to form a government with the Move Forward Party, on 9 August, she and Pheu Thai Party executives walked from the OAI Tower, where the party's headquarters are located, to the neighbouring Thai Summit Tower to discuss with the Move Forward Party leaders about endorsing a candidate for the third round of prime ministerial voting.
=== Hartig net === The Hartig net is formed by an ingrowth of hyphae (often originating from the inner part of the surrounding mantle) into the root of the plant host. The hyphae penetrate and grow in a transverse direction to the axis of the root, and thus form a network between the outer cells of the root axis. In this region fungal and root cells touch, and this is where nutrient and carbon exchange occurs. The depth of penetration differs between species. In Eucalyptus and Alnus the Hartig net is confined to the epidermis, whereas in most gymnosperms the hyphae penetrate more deeply, into the cortical cells or the endodermis. In many epidermal types elongation of cells along the epidermis occurs, increasing surface contact between fungus and root cells. Most cortical type Hartig nets do not show this elongation, suggesting different strategies for increasing surface contact among species.
Hydroxyprogesterone heptanoate (OHPH), also known as hydroxyprogesterone enanthate (OHPE) and sold under the brand names H.O.P., Lutogil A.P., and Lutogyl A.P. among others, is a progestin medication used for progestogenic indications. It has been formulated both alone and in together with estrogens, androgens/anabolic steroids, and other progestogens in several combination preparations (brand names Tocogestan, Trioestrine Retard, and Triormon Depositum). OHPH is given by injection into muscle at regular intervals. OHPH is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It appears to have similar pharmacology to that of the closely related medication hydroxyprogesterone caproate (OHPC). OHPH was first described by 1954 and was introduced for medical use by 1957. It has been used clinically in France and Monaco in the past but is no longer marketed.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.